[Ip-health] NICE: Prostate cancer drug too costly for NHS
Riaz K Tayob
riaz.tayob at gmail.com
Wed Feb 1 23:59:30 PST 2012
[the pure market system for drugs...]
2 February 2012 Last updated at 00:01 GMT
NICE: Prostate cancer drug too costly for NHS
By Smitha Mundasad BBC News
Prostate cancer cell Abiraterone has been shown to extend life for more
than three months
A drug that can extend the life of men with advanced prostate cancer by
more than three months has provisionally been rejected for NHS use.
The health watchdog for England and Wales says the drug's benefits are
not enough to justify the price the NHS has been asked to pay.
Cancer charities have been angered by the decision about abiraterone,
one of the few drugs available to men in the final stages of prostate
A final decision is yet to be made.
Prostate cancer is the most common cancer to affect men in the UK.
The chief executive of the National Institute for Health and Clinical
Excellence (NICE), Sir Andrew Dillon, said the drug was effective, and
one of its key benefits was that it could be taken orally in the
patient's own home.
"We are therefore disappointed not to be able to recommend it for use on
the NHS, however it is an expensive drug," Sir Andrew added.
Abiraterone costs just under £3,000 for one month's supply but has been
offered at a undisclosed discounted price to the NHS.
Cancer charities have criticised the health regulator's decision.
"Quite simply, abiraterone prolongs the life of men with incurable
prostate cancer. The draft decision is a bitter blow to thousands of men
and their families and must be overturned," said Owen Sharp, chief
executive of The Prostate Cancer Charity.
Continue reading the main story
Case study: Ron McCoo, Blackpool
Ron, 59, was diagnosed with prostate cancer in 2010. He has been using
abiraterone for three months. His local health provider currently allows
the drug to be used on an individual basis. He says it has changed his life.
"I have my life back. I have a lot more energy and no pain. My quality
of life is excellent. I wouldn't even know I have cancer now, it's that
"I know it doesn't work for everybody but it certainly works for me. I
would be devastated if it was no longer available on the NHS."
Ron's wife Terri says: "We know NICE has to take a lot of things into
consideration, but when you have a terminal illness an extra fourth
months is very precious."
Prof Peter Johnson, Cancer Research UK's chief clinician, said: "Only
one other drug is available on the NHS that has been shown to prolong
survival but it has more severe side-effects than abiraterone and is
effective in fewer men."
Cancer Research UK, which provided support in the development of the
drug and could benefit from its royalties, said it believed that NICE
might have overestimated the number of people who needed the drug.
It said that if the regulator rethought the criteria used to calculate
the cost-effectiveness of the drug, there is a chance it could be made
available under special arrangements for treating people at the end of
NICE said it had already used the appropriate methods in its review, and
concluded that the number men who would need the drug was too large to
consider such agreements.
Almost 500 men have successfully applied for abiraterone in the past
nine months through the alternative route of the Cancer Drugs Fund in
England, an initiative designed to increase access to drugs.
Until final guidelines are issued by the health regulator, decisions can
continue to be made locally about the use of abiraterone.
Each year 37,000 men are diagnosed with prostate cancer, and more than
10,000 die from it.
More information about the Ip-health